More than 70% of the prescriptions in the US are now filled with generic products, and therefore, the industry has the responsibility to continue to provide safe, effective, and affordable medications. In 2009 GPhA initiated a dialogue between the Industry and the US FDA Office of Generics on Quality by Design (QbD) - a systematic approach for designing quality in our products. To facilitate the discussion between the two, FDA provided hypothetical cases on quality target product profile, compatibility between drug and excipients, formulation and process development, and scale-up and control strategies. While many questions still remain to be addressed, there is general agreement between the industry and the FDA on the benefit of quality by design. The purpose of this presentation is to provide the generic industry perspective on QbD.
Watch the following preview of this presentation.
Would you like to access this content?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
Purchase Technical Presentation
You must purchase this technical presentation using one of the options below.
If you already purchased this content recently, please click here to refresh the system's record of ownerships.
Pricing
| Credits | 0.5 Use credits |
| List Price | $25.00 Buy now |
| AIChE Members | $15.00 Buy now |
| AIChE Undergraduate Student Members | Free Free access |
| AIChE Graduate Student Members | $15.00 Buy now |